Among 32 152 screened men, 50 (0.16%) were excluded because of a history of prostate or breast cancer, 1201 (3.74%) for PSA concentrations greater than 3.0 ng/mL (or >1.5 ng/mL if receiving 5ARIs), 549 (1.71%) for IPSSs greater than 19, and 57 (0.18%) for prostate nodule or induration; these percentages should be interpreted with caution because men who failed screening at earlier screening visits did not complete subsequent screening assessments. Here, KLK3 is linked to breast cancer.